Last Updated:
10 Mar 2026, 03:30:02 PM (IST)
IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCP BSE: IOLCP
NSE
72.58
1.31 (1.84%)
Prev Close
71.27
Open Price
72.5
Volume
1,881,300
Today Low / High
69.42 / 73
52 WK Low / High
57.5 / 126.66
Range
69 - 76
BSE
72.57
1.23 (1.72%)
Prev Close
71.34
Open Price
73.04
Volume
94,899
Today Low / High
69.7 / 73.04
52 WK Low / High
57.51 / 126.6
Range
69 - 76
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 72.58 (target range: 69 - 76), reflecting a change of 1.31 (1.83808%). On the BSE, it is listed at 72.57 (target range: 69 - 76), showing a change of 1.23 (1.72414%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
IOL Chemicals and Pharmaceuticals Limited Graph
IOL Chemicals and Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for IOL Chemicals and Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 72.58, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 72.57 | 73.30 | 65.97 - 80.63 |
| 74.02 | 59.22 - 88.83 | ||
| 74.75 | 52.32 - 97.17 | ||
| Bearish Scenario | 72.57 | 71.84 | 64.66 - 79.03 |
| 71.12 | 56.89 - 85.34 | ||
| 70.39 | 49.28 - 91.51 |
Overview of IOL Chemicals and Pharmaceuticals Limited
ISIN
INE485C01029
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
710,803
Market Cap
20,949,058,389
Last Dividend
1
Official Website
IPO Date
2010-11-08
DCF Diff
57.24
DCF
14
Financial Ratios Every Investor Needs
Stock Dividend of IOLCP
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-17 | February 17, 26 | 1 | 1 | 2026-02-17 | 2026-03-13 | |
| 2025-02-18 | February 18, 25 | 0.8 | 4 | 2025-02-18 | 2025-03-14 | |
| 2024-02-16 | February 16, 24 | 5 | 125 | 2024-02-16 | 2024-03-07 | |
| 2023-02-17 | February 17, 23 | 0.8 | 20 | 2023-02-17 | 2023-03-08 | |
| 2022-02-15 | February 15, 22 | 0.8 | 20 | 2022-02-16 | 2022-03-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,068.19 Cr | 1,413.95 Cr | 654.24 Cr | 0.3163 | 16.75 Cr | 5.65 Cr | 123.60 Cr | 101.07 Cr | 3.44 | 224.71 Cr | 0.0489 |
| 2024-03-31 | 2,118.96 Cr | 1,418.47 Cr | 269.56 Cr | 0.1272 | 17.37 Cr | 6.69 Cr | 159.68 Cr | 134.43 Cr | 4.58 | 260.66 Cr | 0.0634 |
| 2023-03-31 | 2,201.69 Cr | 1,560.54 Cr | 641.15 Cr | 0.2912 | 16.75 Cr | 5.83 Cr | 173.58 Cr | 139.14 Cr | 4.74 | 245.50 Cr | 0.0632 |
| 2022-03-31 | 2,184.02 Cr | 1,869.55 Cr | 571.71 Cr | 0.2618 | 11.14 Cr | 4.50 Cr | 216.19 Cr | 167.67 Cr | 5.71 | 270.54 Cr | 0.0768 |
| 2021-03-31 | 1,946.14 Cr | 1,124.17 Cr | 821.97 Cr | 0.4224 | 7.47 Cr | 4.05 Cr | 553.07 Cr | 444.56 Cr | 15.24 | 611.25 Cr | 0.2284 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 78.17 Cr | 2,382.07 Cr | 694.41 Cr | 1,687.6600 Cr | 117.04 Cr | 38.87 Cr | 360.62 Cr | 1,179.18 Cr | 0.00 Cr | 0.00 Cr | 25.29 Cr | 609.9100 Cr |
| 2024-03-31 | 7.69 Cr | 2,244.40 Cr | 632.89 Cr | 1,611.5100 Cr | 32.76 Cr | 25.07 Cr | 424.84 Cr | 1,036.51 Cr | 0.00 Cr | 0.00 Cr | 66.28 Cr | 560.0000 Cr |
| 2023-03-31 | 1.39 Cr | 2,022.13 Cr | 514.41 Cr | 1,507.7200 Cr | 79.81 Cr | 78.42 Cr | 325.52 Cr | 832.56 Cr | 0.00 Cr | 0.00 Cr | 250.41 Cr | 456.2600 Cr |
| 2022-03-31 | 3.23 Cr | 1,962.30 Cr | 570.02 Cr | 1,392.4800 Cr | 43.95 Cr | 40.72 Cr | 409.89 Cr | 662.49 Cr | 0.00 Cr | 0.00 Cr | 203.71 Cr | 513.4000 Cr |
| 2021-03-31 | 32.34 Cr | 1,610.09 Cr | 349.66 Cr | 1,260.4300 Cr | 2.73 Cr | -29.61 Cr | 295.15 Cr | 560.42 Cr | 4.04 Cr | 0.38 Cr | -284.60 Cr | 290.5500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 178.6200 Cr | -154.1800 Cr | 46.0400 Cr | -34.9300 Cr | 70.4800 Cr | 78.1700 Cr | -213.5500 Cr | 137.9600 Cr | 84.2800 Cr | -23.4800 Cr | 64.2200 Cr |
| 2024-03-31 | 290.0800 Cr | -191.2800 Cr | -92.5000 Cr | 15.9100 Cr | 6.3000 Cr | 7.6900 Cr | -274.1700 Cr | 134.4300 Cr | -46.8700 Cr | -29.3500 Cr | -99.3200 Cr |
| 2023-03-31 | 122.2700 Cr | -120.0000 Cr | -4.1100 Cr | -89.5500 Cr | -1.8400 Cr | 1.3900 Cr | -211.8200 Cr | 188.6500 Cr | 36.8800 Cr | -23.5000 Cr | 84.3700 Cr |
| 2022-03-31 | 93.0500 Cr | -120.5200 Cr | -1.6400 Cr | -60.2400 Cr | -29.1100 Cr | 3.2300 Cr | -153.2900 Cr | 224.8500 Cr | 42.7500 Cr | -35.2200 Cr | -114.7500 Cr |
| 2021-03-31 | 379.7800 Cr | -317.2500 Cr | -58.2800 Cr | 271.5700 Cr | 4.2500 Cr | 32.3400 Cr | -108.2100 Cr | 571.3900 Cr | -57.5300 Cr | -23.4800 Cr | -107.6200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 580.39 Cr | 382.44 Cr | 197.95 Cr | 0.3411 | 37.10 Cr | 20.58 Cr | 0.70 | 51.36 Cr | 0.0355 |
| 2025-09-30 | 567.53 Cr | 368.17 Cr | 199.36 Cr | 0.3513 | 37.09 Cr | 29.97 Cr | 1.02 | 63.96 Cr | 0.0528 |
| 2025-06-30 | 551.69 Cr | 364.33 Cr | 187.36 Cr | 0.3396 | 42.27 Cr | 33.93 Cr | 1.16 | 69.51 Cr | 0.0615 |
| 2025-03-31 | 527.78 Cr | 345.79 Cr | 181.99 Cr | 0.3448 | 44.20 Cr | 31.42 Cr | 1.07 | 67.28 Cr | 0.0595 |
| 2024-12-31 | 523.30 Cr | 354.05 Cr | 169.25 Cr | 0.3234 | 28.19 Cr | 20.53 Cr | 0.70 | 50.94 Cr | 0.0392 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 27.30 Cr | 152.00 Cr | 179.30 Cr | 523.09 Cr | 384.34 Cr | 1,140.62 Cr | 1,192.68 Cr | 2,413.09 Cr | 661.78 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 209.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,687.66 Cr |
| 2025-03-31 | 78.17 Cr | 131.12 Cr | 209.29 Cr | 533.94 Cr | 360.62 Cr | 1,151.34 Cr | 1,179.18 Cr | 2,382.07 Cr | 694.41 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 154.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,659.28 Cr |
| 2024-09-30 | 150.88 Cr | 3.16 Cr | 154.04 Cr | 464.56 Cr | 375.68 Cr | 1,085.68 Cr | 1,120.47 Cr | 2,265.10 Cr | 605.82 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 33.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 31.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 20.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 19.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 29.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2025-03-11 | March 11, 25 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
President of New Product Development
Damandeep Singh
Gender: male
Year Born: 1974
Chief Technology Officer
Gurupur Ganesh Pai
Gender: Not Specified
Year Born: 1952
President of R&D
Kamlesh Jayantilal Ranbhan
Gender: male
Year Born: 1965
Senior Vice President, Company Secretary & Compliance Officer
Abhay Raj Singh
Gender: male
Year Born:
Executive Director
Abhiraj Gupta
Gender: male
Year Born: 1995
President of Engineering
Gopal Singla
Gender: male
Year Born: 1976
Director of Works & Wholetime Director
Kushal Kumar Rana
Gender: male
Year Born: 1969
Chief Financial Officer
Pardeep Kumar Khanna
Gender: male
Year Born: 1970
MD & Whole Time Director
Varinder Gupta
Gender: male
Year Born: 1962
Joint Managing Director & Executive Director
Vikas Gupta
Gender: male
Year Born: 1992
FAQs about IOL Chemicals and Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Varinder Gupta.
What is the current market price of the stock?
The current price is ₹71.37.
What is the 52-week price range?
The range is ₹57.5-126.66.
What is the market capitalization of the company?
The market capitalization is ₹2,094.91 crores.
What is the dividend yield?
The dividend yield is 1.40%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.10.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of IOL Chemicals and Pharmaceuticals Limited (ISIN: INE485C01029) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,094.91 crores and an average daily volume of 710,803 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.